关注慢性髓系白血病的患者报告结局

Focus on the patient-reported outcome of patients with chronic myeloid leukemia

酪氨酸激酶抑制剂使慢性髓系白血病(CML)患者的寿命延长接近正常人群。在临床实践中,有许多重要信息只能从患者处获悉,因此,将患者报告结局(PRO)整合入临床试验和临床实践中已成为当今学术界的关注点之一。文章对PRO的定义及其在CML中的研究进行综述。

Successful use of tyrosine kinase inhibitors prolongs survival of patients with chronic myeloid leukemia and make it dose to normal population. In clinical practice, there is a lot of important information that can only be learned from the patient. Therefore, integrating patient-reported outcome （PRO） into clinical trial and clinical practice has become one of academic concerns. Definition and research of PRO in CML will be reviewed in this paper.